31 May 2018 - PHARMAC is pleased to announce a decision to remove the funding restrictions on candesartan cilexetil, in conjunction with awarding of tenders to the Candestar brand of candesartan resulting from PHARMAC’s 2017/18 annual Invitation to Tender.

Candesartan cilexetil will be open-listed from 1 July 2018, both in the community and in hospitals.

Sole Subsidised Supply Status and Hospital Supply Status will apply to both strengths of Mylan’s Candestar brand of candesartan tablets until 30 June 2021.

Read PHARMAC press release